Fluidigm (NASDAQ:FLDM) had its target price trimmed by Piper Sandler from to in a research report released on Tuesday morning, The Fly reports.

Other analysts have also recently issued reports about the stock. Janney Montgomery Scott cut shares of Fluidigm from a buy rating to a neutral rating in a research note on Wednesday, November 6th. BidaskClub raised shares of Fluidigm from a sell rating to a hold rating in a research note on Saturday, November 2nd. Zacks Investment Research cut shares of Fluidigm from a hold rating to a sell rating in a research note on Friday, January 17th. ValuEngine raised shares of Fluidigm from a hold rating to a buy rating in a research note on Friday, January 3rd. Finally, UBS Group upgraded shares of Fluidigm from a neutral rating to a buy rating and reduced their target price for the stock from $14.00 to $7.00 in a research report on Friday, October 18th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Fluidigm currently has a consensus rating of Buy and a consensus price target of $10.45.

Fluidigm stock traded up $0.01 during trading hours on Tuesday, hitting $3.65. 290,530 shares of the stock were exchanged, compared to its average volume of 830,129. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.44 and a current ratio of 2.89. The stock has a market capitalization of $253.22 million, a P/E ratio of -3.61 and a beta of 2.34. Fluidigm has a 12 month low of $2.12 and a 12 month high of $14.90. The business’s 50-day moving average is $3.75 and its two-hundred day moving average is $4.53.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Monday, February 10th. The medical research company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). The firm had revenue of $32.44 million for the quarter, compared to the consensus estimate of $32.14 million. Fluidigm had a negative return on equity of 20.31% and a negative net margin of 55.26%. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. On average, equities analysts predict that Fluidigm will post -0.5 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in FLDM. Tower Research Capital LLC TRC lifted its position in shares of Fluidigm by 21,055.2% during the third quarter. Tower Research Capital LLC TRC now owns 6,135 shares of the medical research company’s stock worth $29,000 after purchasing an additional 6,106 shares in the last quarter. Banque Cantonale Vaudoise acquired a new position in shares of Fluidigm during the fourth quarter worth approximately $38,000. Citigroup Inc. lifted its position in shares of Fluidigm by 131.7% during the fourth quarter. Citigroup Inc. now owns 14,243 shares of the medical research company’s stock worth $50,000 after purchasing an additional 8,095 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Fluidigm by 45.8% during the fourth quarter. SG Americas Securities LLC now owns 15,120 shares of the medical research company’s stock worth $53,000 after purchasing an additional 4,751 shares in the last quarter. Finally, Bailard Inc. acquired a new position in shares of Fluidigm during the third quarter worth approximately $59,000. Institutional investors own 90.91% of the company’s stock.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Further Reading: How is the LIBOR rate calculated?

The Fly

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.